Lenvatinib Mesilate

甲磺酸仑伐替尼

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameLenvatinib Mesilate
Drug Alias NameLenvatinibum乐伐替尼甲磺酸盐Lenvatinib仑伐替尼甲磺酸盐仑伐替尼 +[17] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 4 antagonistsFibroblast growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 3 antagonists +[10] 
TargetsVascular endothelial growth factor receptor 1Stem cell growth factor receptorVascular endothelial growth factor receptor 3 +[10] 
Therapy Area/IndicationsSolid tumoursRenal InsufficiencyHepatic Insufficiency +[34] 
Global Approved IndicationsThyroid NeoplasmsCarcinoma, Hepatocellular
Approved Indications in ChinaCarcinoma, Hepatocellular
Original Approved Country/TerritoryUnited States
Original Approved Date2015/02/13
Country/TerritoryCzechiaBelgiumBulgaria +[41] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEisai Laboratórios LtdaGuangxi Medical UniversityAsan Medical Center +[21] 
Inactive CompaniesWashington University School Of MedicineUniversity Of MiamiEmory University +[4] 
Active IndicationsSolid tumoursNeoplasm MetastasisUterine Cervical Neoplasms +[18] 
Inactive IndicationsRenal InsufficiencyHepatic InsufficiencyLiver Diseases +[16] 

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG